Study of Neoadjuvant MyocetÂ®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer
This is a prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer
Breast Cancer
DRUG: Liposomal Doxorubicin
Rate of symptomatic (type A) and asymptomatic (type B) cardiac events during the study treatment period, Following 12 months after first dose of the study treatment
pCR in breast (pCRB), At the time of definitive surgery, an expected average of 23 weeks|pCR in breast and axilla (pCRBA), At the time of definitive surgery, an expected average of 23 weeks|Clinical objective response rate (cORR) in the breast and axilla by RECIST criteria version 1.1, At the time of definitive surgery, an expected average of 23 weeks|Residual Cancer Burden (RCB) at surgery following the procedures of the MD Anderson Cancer Center, At the time of definitive surgery, an expected average of 23 weeks|Breast conservation rate at surgery, At the time of definitive surgery, an expected average of 23 weeks|Evaluation of serum biomarkers predictive of cardiotoxicity, Following 12 months after first dose of the study treatment|Percentage of patients with grade 3/4 neutropenia (assessed by CTCAE v.4), Following 12 months after first dose of the study treatment|Time of onset and time of recovery from symptomatic (type A) and asymptomatic (type B) cardiac events (assessed by CTCAE v.4), Following 12 months after first dose of the study treatment|Dose reductions due to treatment toxicity (assessed by CTCAE v.4), Following 12 months after first dose of the study treatment|Dose delays due to treatment toxicity (assessed by CTCAE v.4), Following 12 months after first dose of the study treatment|Number of patients with adverse events and serious adverse events (assessed by CTCAE v.4), Following 12 months after first dose of the study treatment
This is a prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer